OtherBASIC SCIENCE INVESTIGATIONS
Radioimmunotherapy of a Human Lung Cancer Xenograft with Monoclonal Antibody RS7: Evaluation of 177Lu and Comparison of Its Efficacy with That of 90Y and Residualizing 131I
Rhona Stein, Serengulam V. Govindan, Susan Chen, Linda Reed, Heidi Richel, Gary L. Griffiths, Hans J. Hansen and David M. Goldenberg
Journal of Nuclear Medicine June 2001, 42 (6) 967-974;
Rhona Stein
Serengulam V. Govindan
Susan Chen
Linda Reed
Heidi Richel
Gary L. Griffiths
Hans J. Hansen
In this issue
Radioimmunotherapy of a Human Lung Cancer Xenograft with Monoclonal Antibody RS7: Evaluation of 177Lu and Comparison of Its Efficacy with That of 90Y and Residualizing 131I
Rhona Stein, Serengulam V. Govindan, Susan Chen, Linda Reed, Heidi Richel, Gary L. Griffiths, Hans J. Hansen, David M. Goldenberg
Journal of Nuclear Medicine Jun 2001, 42 (6) 967-974;
Radioimmunotherapy of a Human Lung Cancer Xenograft with Monoclonal Antibody RS7: Evaluation of 177Lu and Comparison of Its Efficacy with That of 90Y and Residualizing 131I
Rhona Stein, Serengulam V. Govindan, Susan Chen, Linda Reed, Heidi Richel, Gary L. Griffiths, Hans J. Hansen, David M. Goldenberg
Journal of Nuclear Medicine Jun 2001, 42 (6) 967-974;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti-Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells
- Radioimmunotherapy of Breast Cancer Metastases with {alpha}-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y
- Therapeutic Potential of 90Y- and 131I-Labeled Anti-CD20 Monoclonal Antibody in Treating Non-Hodgkin's Lymphoma with Pulmonary Involvement: A Monte Carlo-Based Dosimetric Analysis
- 89Zr as a PET Surrogate Radioisotope for Scouting Biodistribution of the Therapeutic Radiometals 90Y and 177Lu in Tumor-Bearing Nude Mice After Coupling to the Internalizing Antibody Cetuximab
- Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with 90Y or 177Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy
- Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody
- Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu?
- Optimization of Radioimmunotherapy of Renal Cell Carcinoma: Labeling of Monoclonal Antibody cG250 with 131I, 90Y, 177Lu, or 186Re
- Low-Dose Radioimmunotherapy (90Y-PAM4) Combined with Gemcitabine for the Treatment of Experimental Pancreatic Cancer
- Improved Iodine Radiolabels for Monoclonal Antibody Therapy
- 90Y-DOTA-hLL2: An Agent for Radioimmunotherapy of Non-Hodgkin's Lymphoma